Search by GESP name  
   

 

MET  
    


    
      Official symbol:  MET
      Full name:  MET proto-oncogene, receptor tyrosine kinase
      Location:  7q31.2
      Also known as:  HGFR, DFNB97, RCCP2
      Entrez ID:  4233
      Ensembl ID:  ENSG00000105976
      Summary:  This gene encodes a member of the receptor tyrosine kinase family of proteins and the product of the proto-oncogene MET. The encoded preproprotein is proteolytically processed to generate alpha and beta subunits that are linked via disulfide bonds to form the mature receptor. Further processing of the beta subunit results in the formation of the M10 peptide, which has been shown to reduce lung fibrosis. Binding of its ligand, hepatocyte growth factor, induces dimerization and activation of the receptor, which plays a role in cellular survival, embryogenesis, and cellular migration and invasion. Mutations in this gene are associated with papillary renal cell carcinoma, hepatocellular carcinoma, and various head and neck cancers. Amplification and overexpression of this gene are also associated with multiple human cancers. [provided by RefSeq, May 2016]

    

    
  Overall distribution
    
  Tissue specific distribution
    
 
  
 
Expression restricted in 8 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Gscore (Amp):  0.52  
Gscore (Del):  0.00  
 
Recurrently amplified in 4 cancer type(s)
   

    
  Overall distribution
    
  Tissue specific distribution
    
 
Mscore:  0.31  (Driver)
 
Recurrently mutated in 1 cancer type(s)
   

    
  Overall
    
  Tissue specific
    
 
Total fusion occurrence:  20  (Driver)
 
Fusions detected in 10 cancer type(s)
 
 

    
  Overall
    
  Tissue specific
    
   STRONGLY SELECTIVE     
   

    
      Functional class:  Kinase (protein kinase)
      JensenLab PubMed score:  2013.66  (Percentile rank: 97.90%)
      PubTator score:  1522.99  (Percentile rank: 97.67%)
      Target development/druggability level:  TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action.
      Tractability (small molecule):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets
      Tractability (antibody):  Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets

    







Contact us | | Terms & Conditions.
Copyright © 2020 University of Pennsylvania. All Rights Reserved.